Gilead, an American biotechnology company, has finalized their $4.9B acquisition of Forty Seven, a clinical-stage immuno-oncology company.
“This agreement builds upon Gilead’s presence in immuno-oncology and adds significant potential to our clinical pipeline. Magrolimab complements our existing work in hematology, adding a non-cell therapy program that complements Kite’s pipeline of cell therapies for hematological cancers.”
Daniel O’Day, CEO of Gilead Sciences
The primary asset Gilead gained in this acquisition was Magrolimab, an antibody against signals that prevent macrophages from consuming cancer cells, expanding Gilead’s offerings when it comes to hematological cancers.